EMC Capital Management’s Novavax NVAX Stock Holding History

EMC Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$69K	–	297
2022 Q2	$69K	Hold	1,000	–	–	0.06%	254
2022 Q1	$74K	Hold	1,000	–	–	0.05%	268
2021 Q4	$143K	Hold	1,000	–	–	0.08%	90
2021 Q3	$149K	Hold	1,000	–	–	0.08%	99
2021 Q2	$190K	Hold	1,000	–	–	0.11%	99
2021 Q1	$181K	Hold	1,000	–	–	0.13%	91
2020 Q4	$112K	Buy	+1,000	New	+$106K	0.09%	93

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

EMC Capital Management's NVAX Position: Q3 2022 in Review

EMC Capital Management sold out of Novavax (NVAX) in Q3 2022, closing a stake of 1,000 shares — an estimated $69K sold.

EMC Capital Management first reported a position in NVAX in Q4 2020 and held it in 7 quarters. The position peaked at $190K in Q2 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

EMC Capital Management reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
EMC Capital Management sold 1,000 Novavax shares in Q3 2022, an estimated $69K.
EMC Capital Management first reported a position in Novavax in Q4 2020 and held it in 7 quarters.
EMC Capital Management's Novavax position peaked at $190K in Q2 2021.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on EMC Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.